Hikma Pharmaceuticals

Hikma is a multinational pharmaceutical group dedicated to improving the health and wellbeing of people in the markets it serves through the development, manufacturing and marketing of a broad range of solid, liquid and injectable generic and in-licensed pharmaceutical products.
Hikma is a leading generic pharmaceutical company with a significant presence in the Middle East and North Africa (MENA) region, the United States and Europe. It was first listed on the London Stock Exchange in 2005 is now a constituent of the FTSE 100 Index.

London, GB
Size (employees)
7,189 (est)
Hikma Pharmaceuticals was founded in 1978 and is headquartered in London, GB

Hikma Pharmaceuticals Office Locations

Hikma Pharmaceuticals has offices in London, , Beirut, Cairo and in 3 other locations
London, GB (HQ)
13 Hanover Square

Hikma Pharmaceuticals Metrics

Hikma Pharmaceuticals Financial Metrics

Revenue (2015)

£996.7 m

Revenue growth (2014-15), %


Gross profit

£566.2 m

Gross profit margin (2015), %


Market capitalization (21-Mar-2017)

£4.8 b

Closing share price (21-Mar-2017)

Hikma Pharmaceuticals's current market capitalization is £4.8 b.
Hikma Pharmaceuticals's revenue was reported to be £996.7 m in FY, 2015 which is a 3.3% decrease from the previous period.
FY, 2013FY, 2014FY, 2015


£897.6 m£1 b£996.7 m

Revenue growth, %


Cost of goods sold

£395.2 m£441.6 m£430.5 m

Gross profit

£502.4 m£589 m£566.2 m

Gross profit Margin, %


Operating expense total

£270.9 m£310.8 m£302.5 m

Hikma Pharmaceuticals Market Value History

Hikma Pharmaceuticals Online Presence

Hikma Pharmaceuticals News

Hikma Pharmaceuticals Company Life

You may also be interested in